1. Home
  2. STOK vs APPS Comparison

STOK vs APPS Comparison

Compare STOK & APPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STOK
  • APPS
  • Stock Information
  • Founded
  • STOK 2014
  • APPS 2007
  • Country
  • STOK United States
  • APPS United States
  • Employees
  • STOK N/A
  • APPS N/A
  • Industry
  • STOK Biotechnology: Pharmaceutical Preparations
  • APPS Multi-Sector Companies
  • Sector
  • STOK Health Care
  • APPS Miscellaneous
  • Exchange
  • STOK Nasdaq
  • APPS Nasdaq
  • Market Cap
  • STOK 556.7M
  • APPS 534.2M
  • IPO Year
  • STOK 2019
  • APPS N/A
  • Fundamental
  • Price
  • STOK $8.33
  • APPS $4.23
  • Analyst Decision
  • STOK Strong Buy
  • APPS Hold
  • Analyst Count
  • STOK 8
  • APPS 4
  • Target Price
  • STOK $23.83
  • APPS $2.38
  • AVG Volume (30 Days)
  • STOK 830.1K
  • APPS 13.0M
  • Earning Date
  • STOK 03-24-2025
  • APPS 02-05-2025
  • Dividend Yield
  • STOK N/A
  • APPS N/A
  • EPS Growth
  • STOK N/A
  • APPS N/A
  • EPS
  • STOK N/A
  • APPS N/A
  • Revenue
  • STOK $16,742,999.00
  • APPS $483,577,000.00
  • Revenue This Year
  • STOK $105.42
  • APPS N/A
  • Revenue Next Year
  • STOK $15.13
  • APPS $6.49
  • P/E Ratio
  • STOK N/A
  • APPS N/A
  • Revenue Growth
  • STOK 81.08
  • APPS N/A
  • 52 Week Low
  • STOK $5.28
  • APPS $1.18
  • 52 Week High
  • STOK $17.58
  • APPS $6.86
  • Technical
  • Relative Strength Index (RSI)
  • STOK 32.00
  • APPS 53.51
  • Support Level
  • STOK $9.76
  • APPS $5.01
  • Resistance Level
  • STOK $11.11
  • APPS $6.86
  • Average True Range (ATR)
  • STOK 0.88
  • APPS 0.74
  • MACD
  • STOK -0.30
  • APPS -0.04
  • Stochastic Oscillator
  • STOK 2.31
  • APPS 40.77

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.

About APPS Digital Turbine Inc.

Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.

Share on Social Networks: